DUBLIN–(BUSINESS WIRE)–The “Hypertrophic Cardiomyopathy – Pipeline Insight, 2022” clinical trials has been added to ResearchAndMarkets.com’s offering.
This “Hypertrophic Cardiomyopathy- Pipeline Insight, 2022” report provides comprehensive insights about 12+ companies and 12+ pipeline drugs in Hypertrophic Cardiomyopathy pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
The report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Hypertrophic Cardiomyopathy pipeline landscape is provided which includes the disease overview and Hypertrophic Cardiomyopathy treatment guidelines.
The assessment part of the report embraces, in depth Hypertrophic Cardiomyopathy commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Hypertrophic Cardiomyopathy collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
The companies and academics are working to assess challenges and seek opportunities that could influence Hypertrophic Cardiomyopathy R&D. The therapies under development are focused on novel approaches to treat/improve Hypertrophic Cardiomyopathy.
Hypertrophic Cardiomyopathy Emerging Drugs Chapters
This segment of the Hypertrophic Cardiomyopathy report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Hypertrophic Cardiomyopathy Emerging Drugs
Mavacamten: MyoKardia
Mavacamten is a first-in-class, oral, allosteric modulator of cardiac myosin in development for the treatment of patients with symptomatic obstructive Hypertrophic Cardiomyopathy (oHCM). In March, 2021, The Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for mavacamten, a novel therapy for symptomatic obstructive Hypertrophic Cardiomyopathy (oHCM). Mavacamten is thought to work by reducing cardiac muscle contractility by inhibiting excessive myosin-actin cross-bridge formation that results in hypercontractility, left ventricular hypertrophy and reduced compliance. In clinical and preclinical studies, mavacamten has consistently reduced biomarkers of cardiac wall stress, lessened excessive cardiac contractility, and increased diastolic compliance.
IMB-1018972: Imbria pharmaceticals
IMB-1018972 is a novel, investigational cardiac mitotrope in development for the treatment of cardiovascular disease. As a partial fatty acid oxidation (pFOX) inhibitor, IMB-101 is designed to shift myocardial substrate utilization in favor of glucose oxidation to generate more ATP per unit of oxygen consumed thereby increasing myocardial metabolic efficiency. It is currently in Phase II stage of development for Hypertrophic Cardiomyopathy and is being developed by Imbria pharmaceticals.
CK274: Cytokinetics
Aficamten (formerly CK-3773274, or CK-274) is an investigational, novel, oral, small molecule cardiac myosin inhibitor discovered by company scientists independent of its collaborations, for the potential treatment of hypertrophic cardiomyopathies (HCM). Aficamten was granted Breakthrough Therapy Designation by the U.S. Food and Drug Administration (FDA) for the treatment of symptomatic obstructive hypertrophic cardiomyopathy (oHCM).Aficamten was designed to reduce the hypercontractility associated with HCM. HCM causes the heart to thicken and stiffen, eventually limiting its ability to pump blood. This happens when myosin, a protein in the muscle responsible for converting chemical energy into the mechanical force that causes muscle contraction, is working too hard to grab or pull on actin, another protein within the sarcomere, resulting in hypercontractility, or too many hands pulling on the rope. Aficamten addresses this hypercontractility by blocking some myosins from pulling, resulting in less contraction, or fewer hands on the rope. In preclinical models, aficamten reversed and reduced thickening and stiffening of the heart.
Hypertrophic Cardiomyopathy: Therapeutic Assessment
This segment of the report provides insights about the different Hypertrophic Cardiomyopathy drugs segregated based on following parameters that define the scope of the report, such as:
Major Players in Hypertrophic Cardiomyopathy
There are approx. 12+ key companies which are developing the therapies for Hypertrophic Cardiomyopathy. The companies which have their Hypertrophic Cardiomyopathy drug candidates in the most advanced stage, i.e. Pre-registration include, MyoKardia.
Hypertrophic Cardiomyopathy: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Hypertrophic Cardiomyopathy therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Hypertrophic Cardiomyopathy drugs.
Key Players
- Novartis
- Imbria Pharmaceuticals
- Cytokinetics
- MyoKardia
Key Products
- Mavacamten
- IMB-1018972
- CK274
- LCZ-696
Key Topics Covered:
Introduction
Executive Summary
Hypertrophic Cardiomyopathy: Overview
- Causes
- Mechanism of Action
- Signs and Symptoms
- Diagnosis
- Disease Management
Pipeline Therapeutics
- Comparative Analysis
Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
Hypertrophic Cardiomyopathy- Analytical Perspective
Late Stage Products (Pre-Registration)
- Comparative Analysis
Mavacamten: MyoKardia
- Product Description
- Research and Development
- Product Development Activities
Last Stage Products (Phase III)
- Comparative Analysis
CK274: Cytokinetics
- Product Description
- Research and Development
- Product Development Activities
Mid Stage Products (Phase II)
- Comparative Analysis
IMB-1018972: Imbria pharmaceticals
- Product Description
- Research and Development
- Product Development Activities
Preclinical and Discovery Stage Products
- Comparative Analysis
Drug name: Company Name
- Product Description
- Research and Development
- Product Development Activities
Inactive Products
- Comparative Analysis
Hypertrophic Cardiomyopathy Key Companies
Hypertrophic Cardiomyopathy Key Products
Hypertrophic Cardiomyopathy- Unmet Needs
Hypertrophic Cardiomyopathy- Market Drivers and Barriers
Hypertrophic Cardiomyopathy- Future Perspectives and Conclusion
Hypertrophic Cardiomyopathy Analyst Views
Hypertrophic Cardiomyopathy Key Companies
Appendix
Companies Mentioned
- Novartis
- Imbria Pharmaceuticals
- Cytokinetics
- MyoKardia
For more information about this clinical trials report visit https://www.researchandmarkets.com/r/ewf2ek
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900